107P - A functional polymorphism located in intron of EGFR affects survival outcome of early-stage non-small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Non-Small Cell Lung Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Mi Jeong Hong
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors M.J. Hong1, J.E. Choi2, S.K. Do3, J.H. Lee3, S.Y. Lee4, J.Y. Park4
  • 1Cell And Matrix Research Institute, Kyungpook National University School of Medicine, 41404 - Daegu/KR
  • 2Cell And Matrix Research Institute, Kyungpook National University School of Medicine, Daegu/KR
  • 3Departments Of Biochemistry And Cell Biology, Kyungpook National University School of Medicine, Daegu/KR
  • 4Department Of Internal Medicine, Kyungpook National University School of Medicine, Daegu/KR



Epidermal growth factor receptor (EGFR) is highly amplified in >60% of NSCLCs and plays an important role in regulating the proliferation, survival, motility, and differentiation of the tumor cells. We searched for potential regulatory single nucleotide polymorphisms (SNPs) in EGFR using RegulomeDB, a database integrating information from the Encyclopedia of DNA Elements (ENCODE) project, and investigated their association with survival after surgery in non-small cell lung cancer (NSCLC).


Six hundred and ninety-eight patients with surgically resected NSCLC were enrolled. Seven SNPs (rs9642391C>G, rs1554718T>C, rs7792797A>C, rs11534100C>T, rs12718945G>T, rs11977660C>T, rs2302535C>A) were selected using RegulomeDB database that functionally annotates the regulatory features of SNPs. All polymorphisms were genotyped using SEQUENOM's MassARRAY® iPLEX assay according to instructions of the manufacturer.


Among the seven SNPs examined in this set, rs9642391C>G were significantly associated with overall survival and disease free survival. Patients with the GG allele were associated with a significantly longer survival time compared with that of CC or CG patients (adjusted HR [aHR] for OS = 0.71, 95% CI 0.58–0.88, P = 0.002; and aHR for DFS = 0.82, 95% CI 0.70–0.97, P = 0.02, under additive genetic model).


In conclusion, this study showed that EGFR rs9642391C>G could predict the survival outcomes of patients with surgically resected early stage NSCLC.

Clinical trial identification

Legal entity responsible for the study

Kyungpook National University


Ministry of Health and Welfare


All authors have declared no conflicts of interest.